Repository logo
 

Elevated Plasma Levels of 3-Hydroxyisobutyric Acid Are Associated With Incident Type 2 Diabetes.

Published version
Peer-reviewed

Type

Article

Change log

Authors

Mardinoglu, Adil 
Gogg, Silvia 
Lotta, Luca A 
Stančáková, Alena 
Nerstedt, Annika 

Abstract

Branched-chain amino acids (BCAAs) metabolite, 3-Hydroxyisobutyric acid (3-HIB) has been identified as a secreted mediator of endothelial cell fatty acid transport and insulin resistance (IR) using animal models. To identify if 3-HIB is a marker of human IR and future risk of developing Type 2 diabetes (T2D), we measured plasma levels of 3-HIB and associated metabolites in around 10,000 extensively phenotyped individuals. The levels of 3-HIB were increased in obesity but not robustly associated with degree of IR after adjusting for BMI. Nevertheless, also after adjusting for obesity and plasma BCAA, 3-HIB levels were associated with future risk of incident T2D. We also examined the effect of 3-HIB on fatty acid uptake in human cells and found that both HUVEC and human cardiac endothelial cells respond to 3-HIB whereas human adipose tissue-derived endothelial cells do not respond to 3-HIB. In conclusion, we found that increased plasma level of 3-HIB is a marker of future risk of T2D and 3-HIB may be important for the regulation of metabolic flexibility in heart and muscles.

Description

Keywords

3-Hydroxyisobutyric acid (3-HIB), Branched-chain amino acids (BCAAs), Insulin resistance, Insulin secretion, T2D, Adipose Tissue, Amino Acids, Branched-Chain, Biological Transport, Body Mass Index, Diabetes Mellitus, Type 2, Endothelial Cells, Fatty Acids, Humans, Hydroxybutyrates, Incidence, Metabolome, Microvessels

Journal Title

EBioMedicine

Conference Name

Journal ISSN

2352-3964
2352-3964

Volume Title

27

Publisher

Elsevier BV
Sponsorship
Medical Research Council (MC_UU_12015/1)
Department of Health (via National Institute for Health Research (NIHR)) (NF-SI-0512-10135)
Department of Health (via National Institute for Health Research (NIHR)) (NF-SI-0617-10149)
European Commission and European Federation of Pharmaceutical Industries and Associations (EFPIA) FP7 Innovative Medicines Initiative (IMI) (1153372)
MRC (MC_PC_13048)